Calliditas Therapeutics
206.2 SEK 0%6 investors are following this company
Calliditas Therapeutics operates in the pharmaceutical industry. The company is specialized in the research and development of medical products, particularly aimed at treating kidney and liver diseases. Examples of specialist areas include squamous cell carcinoma, autoimmune hepatitis, and nephropathy. The company was founded in 2004 and has operations on a global level, with headquarters in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CALTX
Daily low / high price
206.2 / 206.8
SEK
Market cap
12.36B SEK
Turnover
28.27M SEK
Volume
137K
Latest videos
Financial calendar
Interim report
2024-08-13
Interim report
2024-11-11
Annual report
2025-02-20
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
BVF Partners LP | 10.5 % | 11.7 % |
Linc AB (Bengt Julander) | 10.0 % | 11.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Calliditas Therapeutics: Calliditas utläser positiva topline-data från fas 2b-studien TRANSFORM i primär gallkolangit
![Calliditas Therapeutics, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d0fdc296-d621-41b2-97f7-59065f50463e.png)
Calliditas Therapeutics, Audiocast with teleconference, Q2'24
Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics: Lansering av klinisk fas 3-studie med Nefecon i Japan
Calliditas Therapeutics: Calliditas provides setanaxib patent update
Calliditas Therapeutics: Uppdatering från Calliditas avseende patent för setanaxib
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Kommuniké från årsstämman i Calliditas Therapeutics AB (publ)
Finansinspektionen: Flaggningsmeddelande i Calliditas Therapeutics AB
Finansinspektionen: Flaggningsmeddelande i Calliditas Therapeutics AB
Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Calliditas Therapeutics: Calliditas partner STADA får positivt yttrande från CHMP som rekommenderar ett fullständigt godkännande av Kinpeygo[®] för behandling av IgA-nefropati
![Calliditas Therapeutics R&D Day, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/89810995-6d01-4c29-bbd5-b044cdebe1b7.png)